Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…
ORGANIZATION
Think Tank Urges Govt to Look at Drugs with Large Prescription Volumes Too
The Institute for New Era Strategy (INES), a think tank headed by former Pfizer Japan President Ichiro Umeda, unveiled a list of proposals on January 23 calling for more focus on low-cost drugs that are prescribed in large volumes, rather…
To read the full story
Related Article
ORGANIZATION
- Labor Groups Call for Careful Discussions on Cost Effectiveness Assessment
February 19, 2019
- EFPIA Japan Chief Says CEA Selection Criteria Mar Predictability, 5 Billion Yen Sales Threshold “Too Low”
February 19, 2019
- 2019 Is Year to “Get Things Right”: PhRMA Japan Chairman
February 8, 2019
- Sanofi CEO Becomes Chairman of PhRMA
February 6, 2019
- PhRMA Takes Issue with Japan Govt’s Overreliance on ICER, Proposes Point-Based Appraisal Framework
February 5, 2019
Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…
A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…
With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…